RELATIONSHIP BETWEEN ETHINYLESTRADIOL IN CONTRACEPTIVES AND DEEP VEIN THROMBOSIS: A SYSTEMATIC LITERATURE REVIEW
DOI:
https://doi.org/10.56238/ERR01v10n3-034Keywords:
Deep Venous Thrombosis, Oral Contraceptives, EthinylestradiolAbstract
Introduction: Deep venous thrombosis (DVT) is a medical condition that has been linked to the use of combined oral contraceptives (COCs), particularly those with high doses of ethinylestradiol (EE), to an increased risk of DVT.Objective: This systematic review aimed to investigate the association between high-dose EE COC use and DVT development in adult women. Methods: The search was conducted across PubMed, BVS, and Cochrane databases for studies that examined the connection between high-dose EE COC use and DVT in adult women. Results: Three relevant studies were identified, two cohort studies and one clinical trial. The studies demonstrated that high-dose EE COC use is associated with an increased risk of DVT. However, the studies exhibited inconsistencies in the magnitude of the risk. Discussion: The findings suggest that high-dose EE COC use is associated with an elevated risk of DVT. However, further research is warranted to determine the incidence and identify specific risk factors for women using these contraceptives. Conclusion: It is crucial that women using high-dose EE COCs are aware of the DVT risk and engage in discussions with their healthcare providers, with Individualized assessments, considering risk factors and epigenetic factors.
Downloads
References
1. PORTO, C.C.; PORTO, A.L. Clínica Médica na Prática Diária. 2. ed. Rio de Janeiro: Guanabara Koogan, 2022.
2. GIRÃO, M.J.B.C.; SARTORI, M.G.F.; NAZÁRIO, A.C.P.; CASTRO, R.A.
Terapêutica em Ginecologia: Protocolos de Assistência do Departamento de Ginecologia da EPM-Unifesp. 1.ed. Barueri, São Paulo: Editora Manole Ltda, 2012.
3. VIEIRA, A.B.P.L.; RIZZO, G.R.; OLIVEIRA, M.C.B.; GABRIEL, S.A. Riscos de
trombose venosa (TVP) associada ao uso de métodos contraceptivos orais. Revista Corpus Hippocraticum. v.1, n.1, 2023.
4. BRASIL, Ministério da Saúde. Secretaria de Políticas de Saúde. Área Técnica de Saúde da Mulher. Assistência em Planejamento Familiar: Manual Técnico/Secretaria de Políticas de Saúde, Área Técnica de Saúde da Mulher. 4.ed. Brasília: Ministério da Saúde, 2002
5. MAFFEI, F.H.A.; YOSHIDA, W.B.; ROLLO, H.A.; MOURA, R.; SOBREIRA, M.L.;
GIANNINI, M.; LASTÓRIA, S. Doenças Vasculares Periféricas. 5.ed. v.1 e 2. Rio de Janeiro: Guanabara Koogan, 2016.
6. BRITO, M.B.; NOBRE, F.; VIEIRA, C.S. Contracepção Hormonal e Sistema Cardiovascular. Arquivos Brasileiros de Cardiologia, 96(4): e81-e89, abr. 2011.
7. REED, S.; KORO, C.; DIBELLO, J.; BECKER, K.; BAUERFEIND, A.; FRANKE,
C.; HEINEMANN, K. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. European Journal of Contraception and Reproductive Health Care, v. 26, n. 6, p. 439–446, 2021.
8. KHIALANI, D.; LE CESSIE, S.; LIJFERING, W.M.; CANNEGIETER, S.C;
ROSENDAAL, F.R.; VLIEG, A. V. H. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. British Journal of Haematology, v. 191, n. 1, p. 90–97, 1 out. 2020.
9. SUGIURA, K.; KOBAYASHI, T.; OJIMA, T. The epidemiological characteristics of thromboembolism related to oral contraceptives in Japan: Results of a national survey. Journal of Obstetrics and Gynaecology Research, v. 47, n. 1, p. 198–207, 1 jan. 2021.
10. MACHADO, R. B.; POLITANO, C. A. Anticoncepcionais orais contendo somente progestagênio. Federação Brasileira das Associações de Ginecologia e Obstetrícia. Febrasgo Position Statement, [s. l], v. 4, p. 1-6, abr. 2022.
11. PNUD. United Nations Development Programme. Human development report 2023/2024. Breaking the gridlock. Reimagining cooperation in a polarized world. [s.d.], 2024.
